We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Read MoreHide Full Article
Accuray Incorporated (ARAY - Free Report) reported third-quarter fiscal 2025 loss per share of a cent compared with the year-ago period’s loss of 6 cents. The bottom line surpassed the Zacks Consensus Estimate by 80%.
ARAY’s Revenues in Detail
Accuray registered quarterly revenues of $113.2 million, up 11.9% year over year. The figure beat the Zacks Consensus Estimate by 10.9%.
The overall top-line growth was driven by robust growth in product revenue and solid demand for its CyberKnife system.
ARAY’s shares moved south 4.3% and closed at $1.55 on Wednesday. The company’s shares have lost 21.7% in the year-to-date period compared with the industry’s 9.1% decline. The broader S&P 500 Index has lost 5.9% in the same time frame.
Image Source: Zacks Investment Research
ARAY’s Segmental Details
Accuray derives revenues from two sources — Products and Services.
In the fiscal third quarter, Product revenues increased 15.6% from the year-ago quarter’s level to $57.3 million.
Services revenues improved 8.5% year over year to $55.9 million.
Gross product orders totaled $71.2 million, down 20.1% year over year. The book-to-bill ratio was 1.2 in the fiscal third quarter compared with 1.8 in the year-ago quarter.
ARAY’s Margin Trend
In the quarter under review, Accuray’s gross profit improved 8.8% year over year to $31.6 million. Gross margin contracted 80 basis points to 27.9%.
Selling and marketing expenses decreased 11.7% year over year to $9.1 million. Research and development expenses decreased 1.8% year over year to $10.7 million. General and administrative expenses also declined 13.3% year over year to $10.8 million. Total operating expenses of $30.6 million decreased 9.1% year over year.
Operating profit totaled $1 million against the prior-year quarter’s operating loss of $4.6 million.
ARAY’s Financial Position
Accuray exited the third quarter of fiscal 2025 with cash and cash equivalents of $77.8 million compared with $62.6 million at the end of the second quarter of fiscal 2025.
Total debt (including short-term debt) at the fiscal third-quarter end was $173.8 million compared with $175.5 million at the end of the second quarter of fiscal 2025.
Accuray Incorporated Price, Consensus and EPS Surprise
Due to the recent tariff announcements and their estimated impact on product volume, Accuray is adjusting revenue guidance for fiscal 2025.
The company now expects revenues in the range of $452-$460 million compared with the previous guidance of $463-$475 million. The Zacks Consensus Estimate is pegged at $469.8 million.
Our Take
Accuray’s third-quarter fiscal 2025 earnings and revenues beat their respective estimates. Per the third-quarter earnings call, Accuray's growth was primarily driven by strong revenue growth, supported by robust demand across both developed and emerging markets. An increase in product revenue, attributed to a 23% rise in unit volume and strong uptake of their expanded product portfolio, along with growth in service revenue, played key roles.
The company achieved a healthy book-to-bill ratio of over 1.2x, with 35% of orders from equipment replacements and the rest from capacity expansions, indicating sustainable customer demand. Operational improvements, effective pricing strategies, and a focus on working capital efficiency also contributed to profitability.
However, despite strong results, Accuray faced a setback from China tariffs, which caused deferred shipments and a $1.4 million gross margin impact, lowering margins to 27.9%. The company also anticipates a $10–$15 million product volume pressure due to reduced China sales, with ongoing trade policy uncertainty posing short-term risk.
FMS’ earnings beat estimates in three of the trailing four quarters and met in one, delivering an average surprise of 15.67%. The company is expected to release first-quarter results next month.
FMS’ shares have gained 10.3% so far this year.
Masimo, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 20% for 2025.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 14.41%. Its shares have risen 58.5% compared with the industry’s 3.9% growth year to date. The company is expected to release first-quarter results in May.
MASI’s shares have lost 1.3% so far this year.
AdaptHealth, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 16.7% for 2025. The company’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering a negative average surprise of 4.17%. The company is expected to release first-quarter results next month.
AHCO's shares have lost 12.1% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Accuray Incorporated (ARAY - Free Report) reported third-quarter fiscal 2025 loss per share of a cent compared with the year-ago period’s loss of 6 cents. The bottom line surpassed the Zacks Consensus Estimate by 80%.
ARAY’s Revenues in Detail
Accuray registered quarterly revenues of $113.2 million, up 11.9% year over year. The figure beat the Zacks Consensus Estimate by 10.9%.
The overall top-line growth was driven by robust growth in product revenue and solid demand for its CyberKnife system.
ARAY’s shares moved south 4.3% and closed at $1.55 on Wednesday. The company’s shares have lost 21.7% in the year-to-date period compared with the industry’s 9.1% decline. The broader S&P 500 Index has lost 5.9% in the same time frame.
Image Source: Zacks Investment Research
ARAY’s Segmental Details
Accuray derives revenues from two sources — Products and Services.
In the fiscal third quarter, Product revenues increased 15.6% from the year-ago quarter’s level to $57.3 million.
Services revenues improved 8.5% year over year to $55.9 million.
Gross product orders totaled $71.2 million, down 20.1% year over year. The book-to-bill ratio was 1.2 in the fiscal third quarter compared with 1.8 in the year-ago quarter.
ARAY’s Margin Trend
In the quarter under review, Accuray’s gross profit improved 8.8% year over year to $31.6 million. Gross margin contracted 80 basis points to 27.9%.
Selling and marketing expenses decreased 11.7% year over year to $9.1 million. Research and development expenses decreased 1.8% year over year to $10.7 million. General and administrative expenses also declined 13.3% year over year to $10.8 million. Total operating expenses of $30.6 million decreased 9.1% year over year.
Operating profit totaled $1 million against the prior-year quarter’s operating loss of $4.6 million.
ARAY’s Financial Position
Accuray exited the third quarter of fiscal 2025 with cash and cash equivalents of $77.8 million compared with $62.6 million at the end of the second quarter of fiscal 2025.
Total debt (including short-term debt) at the fiscal third-quarter end was $173.8 million compared with $175.5 million at the end of the second quarter of fiscal 2025.
Accuray Incorporated Price, Consensus and EPS Surprise
Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote
Guidance for 2025
Due to the recent tariff announcements and their estimated impact on product volume, Accuray is adjusting revenue guidance for fiscal 2025.
The company now expects revenues in the range of $452-$460 million compared with the previous guidance of $463-$475 million. The Zacks Consensus Estimate is pegged at $469.8 million.
Our Take
Accuray’s third-quarter fiscal 2025 earnings and revenues beat their respective estimates. Per the third-quarter earnings call, Accuray's growth was primarily driven by strong revenue growth, supported by robust demand across both developed and emerging markets. An increase in product revenue, attributed to a 23% rise in unit volume and strong uptake of their expanded product portfolio, along with growth in service revenue, played key roles.
The company achieved a healthy book-to-bill ratio of over 1.2x, with 35% of orders from equipment replacements and the rest from capacity expansions, indicating sustainable customer demand. Operational improvements, effective pricing strategies, and a focus on working capital efficiency also contributed to profitability.
However, despite strong results, Accuray faced a setback from China tariffs, which caused deferred shipments and a $1.4 million gross margin impact, lowering margins to 27.9%. The company also anticipates a $10–$15 million product volume pressure due to reduced China sales, with ongoing trade policy uncertainty posing short-term risk.
ARAY’s Zacks Rank and Other Key Picks
Accuray currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the same medical industry are Fresenius Medical Care (FMS - Free Report) , Masimo (MASI - Free Report) and AdaptHealth (AHCO - Free Report) .
Fresenius Medical, carrying a Zacks Rank #2 at present, has an estimated growth rate of 28.9% for 2025. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
FMS’ earnings beat estimates in three of the trailing four quarters and met in one, delivering an average surprise of 15.67%. The company is expected to release first-quarter results next month.
FMS’ shares have gained 10.3% so far this year.
Masimo, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 20% for 2025.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 14.41%. Its shares have risen 58.5% compared with the industry’s 3.9% growth year to date. The company is expected to release first-quarter results in May.
MASI’s shares have lost 1.3% so far this year.
AdaptHealth, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 16.7% for 2025. The company’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering a negative average surprise of 4.17%. The company is expected to release first-quarter results next month.
AHCO's shares have lost 12.1% so far this year.